Herceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumour cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.

Herceptin SC is a subcutaneous formulation that contains hyaluronidase, which temporarily and reversibly degrades hyaluronan, a gel-like substance that forms a barrier between cells under the skin. This enables the subcutaneous formulation of Herceptin to be rapidly dispersed and absorbed over a greater area.

In the United States, Europe and many other countries, Herceptin SC is approved in combination with chemotherapy for the adjuvant (post-surgery) treatment of HER2-positive early breast cancer and first-line treatment of advanced HER2-positive breast cancer. In Europe and other countries, it is also approved in combination with chemotherapy for the neoadjuvant (pre-surgery) treatment of HER2-positive early breast cancer.

In the United States, Herceptin SC is marketed as Herceptin Hylecta.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

you go to an external page